港股異動 | 中國平安漲4% 參與方正重整投資獲批
格隆匯2月4日丨中國平安(2318.HK)現漲4.11%,報63.4港元,總市值11590億港元。2022年1月31日,中國平安公吿稱,旗下平安人壽收到中國銀保監會出具的《關於中國平安人壽保險股份有限公司股權投資新方正集團的批覆》。公吿顯示,根據《重整投資協議》的約定以及重整主體的債權人對債權清償方案的選擇情況,平安人壽擬出資約482億元人民幣受讓新方正控股發展有限責任公司(簡稱“新方正集團”)約66.51%的股權。中國平安表示,下一步,將嚴格落實批覆要求,與各方積極推進《重整投資協議》及重整計劃約定,有序推進資產交割、經營發展、資產處置等各項事宜。業內人士認為,從新方正集團的資產包來看,裏面包括醫療、金融、北大方正人壽)、信息技術等多個核心板塊,可能都是中國平安所看中的,與其目前構建的“大金融資產”和“大醫療健康”生態圈相契合。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.